Group 1: Overall Industry Outlook - In 2026, the pharmaceutical industry is expected to experience a surge in innovative drugs, a recovery in the CXO sector, transformation in traditional Chinese medicine, contraction of retail pharmacies, restructuring of hospitals, and a wave of mergers and acquisitions, leading to increased industry differentiation and stronger players remaining dominant [1] Group 2: Innovative Drugs - A total of 76 innovative drugs were approved in 2025, marking a 58% increase from the previous year, with over 150 licensing transactions totaling more than $130 billion, indicating robust growth in China's innovative drug sector [3] - Approximately 20 major innovative drugs are anticipated to be approved in China in 2026, covering various therapeutic areas including oncology and rare diseases, with notable examples such as BL-B01D1 for esophageal squamous carcinoma [3][4] Group 3: CXO Sector - The CXO (Contract Research Organization) industry is experiencing a recovery driven by external factors such as U.S. interest rate cuts and increased R&D investments from multinational pharmaceutical companies, alongside domestic demand for CRO services [5][6] - The penetration rate of outsourcing in areas like ADCs and oligonucleotides is expected to rise to 65%, with companies like WuXi AppTec and Kelun Biotech showing strong growth in these segments [6] Group 4: Traditional Chinese Medicine - The Chinese medicine sector is entering an era of refined management, driven by policy upgrades and market innovations, with a focus on quality and cost balance in procurement [7][9] - By the end of 2026, China aims to establish 180 domestic and 30 international standards for traditional Chinese medicine, with the market expected to exceed 1 trillion yuan for the first time in 2024 [9] Group 5: Medical Devices - The medical device industry is shifting from price suppression to innovation-driven growth, with domestic companies rapidly advancing in high-end imaging, surgical robots, and AI medical devices [10] - Chinese medical device companies are increasingly expanding into international markets, with a notable rise in export volumes expected by 2026 [10] Group 6: Retail Pharmacies - The offline pharmacy sector is projected to contract significantly due to the growth of O2O and B2C models, with over 15,975 stores closing by September 2025, reflecting a 73% year-on-year increase in closures [12][13] Group 7: Private Hospitals - Private hospitals are facing severe challenges, with an average of 1.4 closures per day in 2024, and this trend is expected to continue into 2026 due to regulatory pressures and financial difficulties [14][15]

Summary of Key Points from Conference Call Records Industry Overview - The conference call discusses the **Chinese innovative pharmaceutical industry** and its global collaboration trends, highlighting the shift from local to global market acceptance of Chinese innovations, including advanced technologies like bispecific antibodies, siRNA, and peptides [1][4]. Core Insights and Arguments - **Global BD Collaboration**: The number of BD (Business Development) collaborations has significantly increased, with China’s License Out transactions surpassing License In for the first time, indicating a shift in international transaction dynamics and enhancing China's global influence [1][4]. - **Investment Environment**: The global investment environment is improving, with emerging sectors like ADC drugs, bispecific CAR-T therapies, and peptides attracting more funding due to technological breakthroughs and clinical value realization. Expectations of interest rate cuts by the Federal Reserve and liquidity easing are anticipated to further boost investment levels [1][6]. - **Record High Transactions**: Chinese innovative pharmaceutical companies have seen record highs in upfront payments and total transaction amounts, with Chinese assets accounting for over 30% of global outbound transactions. The number of first-in-class drugs developed by Chinese companies ranks second globally [1][7]. - **Emerging Trends**: The innovative drug industry is expected to maintain strong growth momentum through 2026, driven by supportive domestic policies and the entry of leading companies into harvest periods, with a focus on new technologies like ADC and GLP-1 [2][3]. Additional Important Content - **Policy Support**: The Chinese government is increasing support for the innovative drug industry, with new measures aimed at enhancing quality and market scale, including the introduction of anti-involution measures in the 11th batch of centralized procurement [2][19]. - **CRO Industry Outlook**: The CRO (Contract Research Organization) sector is expected to continue its upward trend, driven by the rise of AI drug development technologies and a recovering investment environment in domestic biomedicine [3][26]. - **Biotech Growth**: Domestic biotech companies are entering a harvest phase, with significant revenue growth projected, indicating a robust recovery in the sector [24]. - **Emerging Treatment Areas**: The conference highlights the potential of new therapies in areas such as atopic dermatitis, psoriasis, and chronic obstructive pulmonary disease (COPD), with advancements in dual antibody therapies and PDE34 inhibitors [15][17]. Conclusion - The Chinese innovative pharmaceutical industry is poised for significant growth, supported by favorable policies, increasing global collaboration, and emerging treatment technologies. The focus on high-quality development and strategic investments in leading companies will be crucial for sustaining this momentum through 2026 and beyond [2][25].

Group 1 - The CRO (Contract Research Organization) sector in the Hong Kong stock market has shown strong performance, with notable gains across various companies [1] - Specifically, Kailaiying has increased by over 7%, while Tigermed and Zhaoyan Pharmaceutical have risen by over 5% [1] - Other companies such as WuXi AppTec and Kanglong Chemical have seen increases of over 3%, and WuXi Biologics and Kingsoft have gained over 2% [1]

Core Viewpoint - The CRO and CDMO sectors are experiencing a collective rise in stock prices, driven by a combination of recovering demand and supply-side improvements, with expectations for profitability and valuation to increase simultaneously, referred to as a "Davis Double Play" [1][2] Group 1: Stock Performance - Key stocks in the CRO sector have seen significant gains, with Kelaiying up 6.27% to HKD 82.2, Tigermed up 5.48% to HKD 48.92, and Zhaoyan New Drug up 5.19% to HKD 23.52 [1] - Other notable increases include Kanglong Chemical up 3.37% to HKD 22.68 and WuXi AppTec up 3.12% to HKD 109.1 [1] Group 2: Industry Outlook - According to Zhongtai Securities, the CRO and CDMO industries are expected to benefit from a combination of external and internal demand recovery, with supply gradually clearing [1] - The anticipated easing of monetary policy in late 2024 and subsequent geopolitical negotiations in 2025 are expected to improve market sentiment and drive demand recovery [1] - The industry is projected to see significant policy support and the realization of large-scale domestic innovative drug business development starting in 2025 [1] Group 3: Order Growth and Market Dynamics - Industrial insights from Xingye Securities indicate that many CROs are experiencing accelerated order signing, with project volumes achieving double-digit growth [2] - There is a noted upward trend in pricing for experimental monkeys, safety evaluation quotes, and clinical project costs since Q4, reflecting strong customer demand [2] - The global positioning of Chinese CDMOs in the supply chain remains irreplaceable, and the anticipated Federal Reserve interest rate cuts are expected to boost early-stage global R&D demand [2]

Group 1 - The CRO concept stocks have collectively risen, with notable increases in share prices for companies such as Kintor Pharmaceutical (6.27% increase), Tigermed (5.48% increase), and WuXi AppTec (3.12% increase) [1] - Zhongtai Securities believes that the CRO and CDMO industries are experiencing a resonance in both domestic and foreign demand, with a gradual clearing of supply [1] - The demand side is expected to gradually recover due to multiple factors, including the onset of overseas interest rate cuts in Q4 2024, improved pessimistic expectations from geopolitical negotiations in Q2 2025, and the rollout of major domestic innovative drug business development [1] Group 2 - Industrial growth in the CRO sector is being driven by the overseas expansion of innovative drug business development and a stabilization in financing, leading to a double-digit growth in new orders [2] - There is a rising trend in pricing for experimental monkeys, safety evaluation quotes, and clinical project prices since Q4, indicating strong customer demand [2] - The global position of Chinese CDMO in the supply chain is deemed irreplaceable, and the anticipated interest rate cuts by the Federal Reserve are expected to boost early-stage global research and development demand [2]

Group 1 - The majority of Hong Kong pharmaceutical stocks experienced an increase, with 恒瑞医药 (Hengrui Medicine) and 和黄医药 (Hutchison China MediTech) rising over 3% [1] - 康龙化成 (Crown Bioscience), 石药集团 (Shijiazhuang Pharmaceutical Group), and 泰凌医药 (Tianling Pharmaceutical) saw increases of over 2% [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | ...

公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | ...

Core Insights - The Chinese CRO industry encompasses the entire drug lifecycle, including drug research services (CRO), pharmaceutical manufacturing services (CMO/CDMO), and sales services (CSO) [1][2][5] - The industry is characterized by a lack of significant upstream relationships, with some mature markets extending services to drug marketing and patent commercialization [2] Industry Overview - The CRO industry in China is segmented into three main phases: research, production, and sales, covering preclinical and clinical stages [1] - Preclinical services focus on drug discovery, compound synthesis, and formulation development, while clinical services involve clinical trials and data analysis [1] - The production phase includes various drug types, such as chemical APIs and biologics, while the sales phase centers on demand channel management for pharmaceutical companies and healthcare institutions [1] Regional Distribution - The distribution of CRO companies in China is highly concentrated in economically developed regions: Beijing (75 companies), Shanghai (59), Jiangsu (43), and Guangdong (38) [7] - These four regions account for a significant share of the total CRO enterprises, while other provinces show limited presence [7] Key Players and Performance - Major listed companies in the CRO sector include WuXi AppTec, Kanglong Chemical, Tigermed, and others [1][5] - In 2024, WuXi AppTec leads with revenue of 29.052 billion yuan, while Chengdu XianDao boasts the highest gross margin at 57.5% [12] - Other notable companies include Kanglong Chemical with 70.47 billion yuan in preclinical revenue and a gross margin of 44.92% [12] Investment Trends - Companies in the CRO sector are focusing on core business optimization, technological enhancement, and strategic collaborations [14] - Recent investments include WuXi AppTec's acquisition of stakes in various companies to strengthen its supply chain and capabilities [16] - Chengdu XianDao has partnered with the Gates Foundation for new drug development, while Kanglong Chemical is acquiring a majority stake in a biotech firm to enhance its technical platform [16]

Core Viewpoint - The medical ETF (512170) has shown significant performance, with a daily increase of over 5% and reaching a 20-day high, indicating strong market interest and potential growth in the healthcare sector [1]. Group 1: ETF Performance - The medical ETF opened high on January 6 and saw a peak increase of over 1%, with a trading volume exceeding 350 million yuan [1]. - The ETF has recorded five consecutive days of gains, reflecting a robust upward trend in the healthcare sector [1]. Group 2: Component Stocks - Brain-computer interface stocks, specifically Sanbo Brain Science and Meihua Medical, both hit the daily limit up of 20%, marking two consecutive days of gains [1]. - Conversely, the CXO sector experienced a pullback, with Tigermed seeing a decline of over 1% [1]. Group 3: Market Insights - Tesla CEO Elon Musk announced that Neuralink plans to start large-scale production of brain-computer interface devices in 2026, which could accelerate the commercialization of this technology [2]. - The National Medical Products Administration of China held a meeting to expedite the review and approval of related medical devices, indicating regulatory support for the industry [2]. Group 4: Industry Outlook - CITIC Securities highlighted that China's brain-computer interface technology is relatively advanced globally, which may lead to the emergence of leading companies in this field and enhance valuations in the secondary market [3]. - Zhongtai Securities noted a potential rebound in the pharmaceutical sector after four years of decline, driven by the realization of innovative drug export logic and industry recovery due to policy reforms [3].